BRPI0510654A - formulações de interferon em hidrogel - Google Patents

formulações de interferon em hidrogel

Info

Publication number
BRPI0510654A
BRPI0510654A BRPI0510654-0A BRPI0510654A BRPI0510654A BR PI0510654 A BRPI0510654 A BR PI0510654A BR PI0510654 A BRPI0510654 A BR PI0510654A BR PI0510654 A BRPI0510654 A BR PI0510654A
Authority
BR
Brazil
Prior art keywords
interferon
hydrogel
formulations
hydrogel formulations
relates
Prior art date
Application number
BRPI0510654-0A
Other languages
English (en)
Inventor
Silvia Pompili
Pierandrea Esposito
Maria Dorly Del Curto
Ilaria Zambaldi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0510654A publication Critical patent/BRPI0510654A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

FORMULAçõES DE INTERFERON EM HIDROGEL. A presente invenção refere-se a formulações farmacêuticas de hidrogel de poloxâmero contendo um interferon. Em particular, a invenção refere-se a formulações em hidrogel de liberação sistemática de interferon-beta, a um método de preparação e ao uso das mesmas.
BRPI0510654-0A 2004-05-17 2005-05-13 formulações de interferon em hidrogel BRPI0510654A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04076496 2004-05-17
US57921804P 2004-06-14 2004-06-14
PCT/EP2005/052219 WO2005110466A1 (en) 2004-05-17 2005-05-13 Hydrogel interferon formulations

Publications (1)

Publication Number Publication Date
BRPI0510654A true BRPI0510654A (pt) 2007-11-20

Family

ID=34928234

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510654-0A BRPI0510654A (pt) 2004-05-17 2005-05-13 formulações de interferon em hidrogel

Country Status (14)

Country Link
US (1) US7879320B2 (pt)
EP (1) EP1748788A1 (pt)
JP (1) JP2007538048A (pt)
KR (1) KR20070012464A (pt)
CN (1) CN1984673A (pt)
AR (1) AR048963A1 (pt)
AU (1) AU2005244448B2 (pt)
BR (1) BRPI0510654A (pt)
CA (1) CA2566364A1 (pt)
EA (1) EA012205B1 (pt)
NZ (1) NZ550926A (pt)
UA (1) UA88300C2 (pt)
WO (1) WO2005110466A1 (pt)
ZA (1) ZA200609412B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP4658961B2 (ja) * 2003-12-11 2011-03-23 アレス トレーディング エス．エー． 安定化されたインターフェロン液体製剤
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
EP1893174A2 (en) * 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR100918645B1 (ko) * 2007-12-14 2009-09-25 포항공과대학교 산학협력단 하이드로겔의 상변화 원격 제어 방법 및 이를 이용한 약물전달 방법
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
CN101559036B (zh) * 2008-04-18 2012-02-08 上海医药工业研究院 一种阴道用避孕凝胶组合物及其制备方法和应用
ES2369101B2 (es) * 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.
RU2013119982A (ru) * 2010-10-01 2014-11-20 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Количественное определение и характеризация аллергенов
EP2734557B1 (en) * 2011-07-20 2022-09-07 UroGen Pharma Ltd. Production of thermoreversible hydrogels for therapeutic applications
CN102989036B (zh) * 2011-09-10 2015-10-21 浙江海正药业股份有限公司 应用于血管吻合术的含有肝素-泊洛沙姆复合物的水凝胶及其制备方法
CN102989035B (zh) * 2011-09-10 2014-12-17 浙江海正药业股份有限公司 一种应用于血管吻合术的水凝胶及其制备方法
RU2496478C1 (ru) * 2012-10-19 2013-10-27 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Состав в форме геля для лечения ран и ожогов различной этиологии, обеспечивающий условия для эпителизации
JP6527697B2 (ja) * 2013-01-28 2019-06-05 国立大学法人 熊本大学 タンパク質を安定化させたゲル状製剤
WO2014160377A1 (en) * 2013-03-13 2014-10-02 Invivo Therapeutics Corporation Crosslinkable trehalose for the covalent incorporation in hydrogels and methods of use
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
KR20170057451A (ko) * 2014-10-01 2017-05-24 에이엘에스 마운틴 엘엘씨 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
WO2019241985A1 (zh) * 2018-06-22 2019-12-26 温州医科大学 一种水凝胶、含其的药物组合物及其应用
CN110655660B (zh) * 2019-09-05 2020-10-20 北京科技大学 具有刺激响应性的单荧光分子白光发射水凝胶的制备方法
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4469228A (en) 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA2011423A1 (en) * 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PT1224940E (pt) 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
JP2001526033A (ja) 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
CN1187094C (zh) 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
NZ517184A (en) 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6586785B2 (en) 2000-06-29 2003-07-01 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE60130580T2 (de) 2000-12-27 2008-06-12 Ares Trading S.A. Lipidmikropartikel mittels kryogenischer mikronisierung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
BR0213298A (pt) * 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
EP1471891A4 (en) 2002-02-08 2007-04-11 Alkermes Inc POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE
JP4610154B2 (ja) * 2002-05-30 2011-01-12 大塚製薬株式会社 注射用製剤
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
JP4658961B2 (ja) 2003-12-11 2011-03-23 アレス トレーディング エス．エー． 安定化されたインターフェロン液体製剤
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона

Also Published As

Publication number Publication date
AU2005244448B2 (en) 2011-03-17
ZA200609412B (en) 2008-07-30
KR20070012464A (ko) 2007-01-25
CN1984673A (zh) 2007-06-20
EA200602137A1 (ru) 2007-04-27
AR048963A1 (es) 2006-06-14
US7879320B2 (en) 2011-02-01
UA88300C2 (ru) 2009-10-12
WO2005110466A1 (en) 2005-11-24
US20070248674A1 (en) 2007-10-25
EA012205B1 (ru) 2009-08-28
JP2007538048A (ja) 2007-12-27
CA2566364A1 (en) 2005-11-24
NZ550926A (en) 2010-01-29
EP1748788A1 (en) 2007-02-07
AU2005244448A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0510654A (pt) formulações de interferon em hidrogel
NO20065860L (no) Stabiliserte flytende interferonformuleringer
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BRPI0212137A2 (pt) diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
BRPI0912411A2 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
DK1406633T3 (da) Forbedret lægemiddeltilførsel i transdermale systemer
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
ATE447396T1 (de) Pharmazeutisches vaginales gel mit tenofovir
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
DE60326859D1 (de) Arzneimittelverabreichung
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica
MY151121A (en) Hsa-free stabilized interferon liquid formulations
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
DE602005008607D1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
NO20065791L (no) Asyklovir-formuleringer
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
DK1377316T3 (da) Farmaceutisk sammensætning på grundlag af azalider til lokal anvendelse i oftalmologien
IL180900A0 (en) Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
DK1537132T3 (da) Salt af mortin-6-glucuronid
ITMI20042356A1 (it) Composizione farmaceutica orodisperdibile e procedimento per prepararla
SI1881838T1 (sl) Protitumorsko sredstvo na osnovi BCG cepiva, postopek za pripravo in uporabo le-tega
NO20065853L (no) Hydrogelinterferonformuleringer
ITMO20030229A0 (it) Inalatore per preparati in polvere.
AU2003283508A8 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.